A public-private council report outlining industry views on Japan’s drug pricing systems drew little discussion at a meeting of the…
HOME > LATEST
LATEST
-
REGULATORY Payers, Providers Clash over Fate of Fee Premiums for Generic Use
October 20, 2025
-
BUSINESS Meiji Completes New Facilities to Restart Domestic Production of 6-APA
October 20, 2025
-
BUSINESS Chiesi Japan to Expand Workforce Tenfold by 2030 on Back of New Drug Filings
October 20, 2025
-
BUSINESS iPark, KoreaBIO Ink MOU to Fuel Japan-Korea Cooperation in Life Sciences
October 20, 2025
-
BUSINESS Novo, JAST Join Hands to Raise Awareness of Obesity
October 20, 2025
-
REGULATORY MHLW Panel Launches Full Debate on Drug Coverage Reform; LLPs, Biologics, OTC-Like Meds in Focus
October 17, 2025
-
ORGANIZATION Wholesalers to Broaden Lobbying Push to Include Ishin amid Political Shift: Leader
October 17, 2025
-
ORGANIZATION JPMA Chief Renews Call for Reflecting Inflation and Wage Hikes in Drug Pricing
October 17, 2025
-
BUSINESS Taiho Bags Haihe’s PI3Kα Inhibitor Risovalisib
October 17, 2025
-
BUSINESS Lilly Japan Teams Up with 23 Medical Societies to Strengthen Obesity Care
October 17, 2025
-
REGULATORY GSK’s Blenrep, BMS’s Inrebic Absent from October Listing Roster
October 17, 2025
-
REGULATORY Shionogi/Sage’s Depression Drug Up for MHLW Panel Review on Oct. 30
October 17, 2025
-
REGULATORY SanBio’s Akuugo Nears Shipment with MHLW Panel Backing; Sakigake Tag OK’ed for Bayer Gene Therapies
October 17, 2025
-
BUSINESS Viatris Snaps Up Japan’s Aculys Pharma, Gains 2 CNS Assets
October 17, 2025
-
BUSINESS Organon Bids Farewell to 1990s Blockbusters Lipovas and Renivace in Japan
October 16, 2025
-
REGULATORY Chuikyo Clears Listing for Yorvipath and More Drugs; Zero Premium Rule Weighs Yet Again
October 16, 2025
-
REGULATORY Japan to Clarify Criteria for Upward Price Adjustments under CEA Scheme
October 16, 2025
-
REGULATORY Deeper CEA Price Cuts Mooted for “Cost Increase” Products: FY2026 Reform Debate
October 16, 2025
-
REGULATORY Listing OK’ed for Krystal’s Vyjuvek Gel, Japan’s First Topical Gene Therapy
October 16, 2025
-
REGULATORY Chuikyo Urges Stricter Pricing Rules for Conditionally Approved Regenerative Medicines
October 16, 2025
ページ
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
In the complex tapestry of leadership, awareness isn’t just a desirable trait; it’s the bedrock upon which success is built. It’s the lens through which leaders perceive, interpret, and navigate the ever-shifting landscape of their organizations and industries. Without it,…
Japan’s drug wholesalers are facing mounting financial pressure as rising logistics and procurement costs deepen losses on product distribution, even…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…